TLR4 and chorioamnionitis: We assessed the eNAMPT/TLR4 inflammatory pathway as a druggable IAI target in pregnancy utilizing a humanized eNAMPT-neutralizing mAb in a murine model of IAI/chorioamnionitis-induced uterine and neonatal inflammation as well as premature birth.